CareDx, Inc (USD) CareDx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare providers. The company's extensive portfolio features a range of specialized diagnostic solutions for organ monitoring, including: AlloSure Kidney, AlloSure Heart, and AlloSure Lung: Advanced tests employing donor-derived cell-free DNA (dd-cfDNA) technology to assess the health of kidney, heart, and lung transplants, respectively. AlloMap Heart: A gene expression-based solution specifically for heart transplant patients. AlloSeq cfDNA: A broader surveillance tool to measure dd-cfDNA levels in the blood. CareDx also provides cutting-edge human leukocyte antigen (HLA) typing technologies, such as TruSight HLA, an NGS-based high-resolution typing solution; Olerup SSP, which uses sequence-specific primer technology for HLA allele typing; QTYPE for precise HLA typing; and AlloSeq Tx, another high-resolution HLA typing offering. For stem cell transplant recipients, the company offers AlloSeq HCT for chimerism testing. Beyond diagnostics, CareDx develops vital software and digital platforms to streamline transplant patient management. These include Ottr, a dedicated transplant patient management software; XynQAPI, focused on transplant quality tracking and waitlist management; and AlloCare, a mobile application serving as a patient-centric resource for those who have undergone transplantation. The company distributes its products directly to clients, as well as through a network of third-party distributors and sub-distributors. CareDx has forged significant partnerships, including a licensing agreement with Illumina, Inc. for the distribution, development, and commercialization of next-generation sequencing (NGS) products and technologies. Additionally, it collaborates with Cibiltech SAS to commercialize iBox, a software designed for the predictive analysis of kidney allograft loss post-transplantation. Founded in 1998, the company was initially known as XDx, Inc. before rebranding to CareDx, Inc. in March 2014. Its headquarters are located in South San Francisco, California.

CareDx, Inc (USD) Active

1 Tower Place, South San Francisco, CA, US, 94080

Stock Price USD

Price Change

Last Dividend USD

C-

Latest Rating

CDNA's stock peer is CRMD (CorMedix Inc.)

CDNA's stock peer is CSTL (Castle Biosciences, Inc.)

CDNA's stock peer is DRIO (DarioHealth Corp.)

CDNA's stock peer is EMBC (Embecta Corp.)

CDNA's stock peer is EVH (Evolent Health, Inc.)

CDNA's stock peer is FLGT (Fulgent Genetics, Inc.)

CDNA's stock peer is MRVI (Maravai LifeSciences Holdings, Inc.)

CDNA's stock peer is MYGN (Myriad Genetics, Inc.)

CDNA's stock peer is PSNL (Personalis, Inc.)

CDNA's stock peer is VIR (Vir Biotechnology, Inc.)

Healthcare Medical - Diagnostics & Research

CareDx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare providers. The company's extensive portfolio features a range of specialized diagnostic solutions for organ monitoring, including: AlloSure Kidney, AlloSure Heart, and AlloSure Lung: Advanced tests employing donor-derived cell-free DNA (dd-cfDNA) technology to assess the health of kidney, heart, and lung transplants, respectively. AlloMap Heart: A gene expression-based solution specifically for heart transplant patients. AlloSeq cfDNA: A broader surveillance tool to measure dd-cfDNA levels in the blood. CareDx also provides cutting-edge human leukocyte antigen (HLA) typing technologies, such as TruSight HLA, an NGS-based high-resolution typing solution; Olerup SSP, which uses sequence-specific primer technology for HLA allele typing; QTYPE for precise HLA typing; and AlloSeq Tx, another high-resolution HLA typing offering. For stem cell transplant recipients, the company offers AlloSeq HCT for chimerism testing. Beyond diagnostics, CareDx develops vital software and digital platforms to streamline transplant patient management. These include Ottr, a dedicated transplant patient management software; XynQAPI, focused on transplant quality tracking and waitlist management; and AlloCare, a mobile application serving as a patient-centric resource for those who have undergone transplantation. The company distributes its products directly to clients, as well as through a network of third-party distributors and sub-distributors. CareDx has forged significant partnerships, including a licensing agreement with Illumina, Inc. for the distribution, development, and commercialization of next-generation sequencing (NGS) products and technologies. Additionally, it collaborates with Cibiltech SAS to commercialize iBox, a software designed for the predictive analysis of kidney allograft loss post-transplantation. Founded in 1998, the company was initially known as XDx, Inc. before rebranding to CareDx, Inc. in March 2014. Its headquarters are located in South San Francisco, California.

20%

Dcf Rating

20%

Return On Equity

20%

Return On Assets

60%

Debt To Equity

20%

Price To Earnings

40%

Price To Book

Income Statement

Dividend Stats Yield is calculated via trailing-12-month period

Ex-Dividend	Payment Date	Dividend	Yield	Dividend Frequency
Dividend Data Not Exist

Recent News

CareDx Precision Medicine Diagnostics Showcased in Over 30 Abstracts and 9 Oral Presentations at the 2026 American Transplant Congress

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced its participation at the American Transplant Congress (ATC) 2026, taking place June 20–24 in Boston, Massachusetts. Real-world clinical use and scientific advancements involving AlloSure® Kidne.

2026-06-18 07:05:00

CareDx Announces Second KOAR Analysis Published in the Journal of the American Society of Nephrology

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced the publication of a new analysis from the Kidney Allograft Outcomes AlloSure Registry (KOAR), a landmark multi-center study, in the Journal of the American Society of Nephrology (JASN). The se.

2026-06-16 16:05:00

CareDx to Participate in Upcoming Investor Conferences

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced the company will participate in the following investor conferences: Jefferies 2026 Global Healthcare Conference at the Marriot Marquis in New York, NY. Presentation on Wednesday, June 3, 2026,.

2026-05-20 16:01:00

CareDx Announces Dismissal of 2021 Qui Tam Suit

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the dismissal of a qui tam action filed against the Company. On April 23, 2026, the United States District Court for the Eastern District of New York issued an order dismissing the matter. Ther.

2026-05-11 16:05:00

CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the award of inducement grants. On April 30, 2026, as an inducement material to acceptance of employment with CareDx, 23 new employees were awarded restricted stock units (RSUs) for an aggreg.

2026-05-01 16:01:00

CareDx Announces Agreement to Acquire Naveris, A Leader in Viral-Mediated Cancer MRD Surveillance Testing

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced it has entered into a definitive agreement to acquire Naveris, a commercial stage precision oncology diagnostics company with a highly differentiated and Medicare-reimbursed, blood‑based monito.

2026-04-28 16:05:00

CareDx Announces First Quarter 2026 Financial Results

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Financial Highlights Revenue of $118 million, an increase of 39% year-over-year Testing services revenue of $91 m.

2026-04-28 16:01:00

CareDx Announces Presentation of More Than 50 Abstracts Including 16 Oral Presentations at the International Society for Heart and Lung Transplantation's 46th Annual Meeting

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced its participation at the International Society of Heart and Lung Transplantation (ISHLT) 2026 Annual Meeting, taking place April 22–25 in Toronto, Canada. The real-world clinical use and scient.

2026-04-21 16:01:00

CareDx Introduces AlloSeq Nano at EFI 2026, Expanding HLA Typing Portfolio with Long-Read Sequencing

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today introduced AlloSeq Nano, a nanopore‑based HLA (human leukocyte antigen) and ABO blood type genotyping solution, at the European Federation for Immunogenetics (EFI) Conference 2026. AlloSeq Nano is an inn.

2026-04-20 07:05:00

Eurobio scientific signs definitive agreement to acquire CareDx's transplant Lab Product division

EUROBIO SCIENTIFIC SIGNS DEFINITIVE AGREEMENT TO ACQUIRE CAREDX's TRANSPLANT LAB PRODUCT DIVISION Acquisition of CareDx's ‘lab products' portfolio creates new opportunities for growth and innovation in the fast growing transplant diagnostics market Acceleration of Eurobio's strategic plan to become an in-vitro molecular diagnostics (“IVD”) leader Creation of a global leading provider of kits for transplantation genomics Acquisition of a 100% proprietary products portfolio Deeper capabilities and larger scale with technological and commercial complementarities Paris, April 16, 2026 ,8 AM EST Eurobio Scientific (FR0013240934, ALERS, PEA-PME eligible), a leading French group in in-vitro medical diagnostics for transplantation, oncology and infectious diseases, today announces that it has entered into a definitive agreement to acquire the Lab Products division of CareDx, a US global precision medicine company focused on transplantation. Through the acquisition of CareDx's Lab Products division, the transaction brings together two highly complementary portfolios in human leukocyte antigen (“HLA)” typing and transplantation diagnostics.

2026-04-16 02:00:00

Disclaimers

StockQuay.com is not operated by a broker, dealer, or registered investment advisor. Under no circumstances should any information published on StockQuay.com be considered a recommendation to buy, sell, or hold any security. The content on this site and in its associated newsletters is intended solely for informational and educational purposes and does not constitute investment advice or financial recommendations.

Individuals or entities featured or referenced on StockQuay.com may engage in trading activity involving the securities mentioned in any article or report before or after such content is published. These individuals or entities are not affiliated with StockQuay.com, and their inclusion does not imply endorsement or accuracy of their views or actions.

StockQuay.com, its owners, or its affiliates shall not be held liable to any user or third party for any damages or losses arising from the use of content on this website. This includes, but is not limited to, investment losses, loss of profit, loss of data, missed opportunities, or indirect, incidental, or consequential damages.

Data is updated daily and is not guaranteed to be accurate or complete.

Past performance is not indicative of future results. Please conduct your own research or consult with a qualified financial advisor before making any investment decisions